Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands.
Department of Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands.
Front Immunol. 2022 Mar 22;13:864403. doi: 10.3389/fimmu.2022.864403. eCollection 2022.
Autoimmune diseases affect many people worldwide. Current treatment modalities focus on the reduction of disease symptoms using anti-inflammatory drugs which can lead to side effects due to systemic immune suppression. Restoration of immune tolerance by down-regulating auto-reactive cells in an antigen-specific manner is currently the "holy grail" for the treatment of autoimmune diseases. A promising strategy is the use of nanoparticles that can deliver antigens to antigen-presenting cells which in turn can enhance antigen-specific regulatory T cells. In this review, we highlight some promising cell targets (e.g. liver sinusoidal endothelial cells and splenic marginal zone macrophages) for exploiting natural immune tolerance processes, and several strategies by which antigen-carrying nanoparticles can target these cells. We also discuss how nanoparticles carrying immunomodulators may be able to activate tolerance in other antigen-presenting cell types. Finally, we discuss some important aspects that must be taken into account when translating data from animal studies to patients.
自身免疫性疾病影响着全世界许多人。目前的治疗方法侧重于使用抗炎药物来减轻疾病症状,而这些药物可能会因全身免疫抑制而产生副作用。通过以抗原特异性方式下调自身反应性细胞来恢复免疫耐受,目前是治疗自身免疫性疾病的“圣杯”。一种很有前途的策略是使用纳米颗粒将抗原递送给抗原呈递细胞,进而可以增强抗原特异性调节性 T 细胞。在这篇综述中,我们强调了一些有前途的细胞靶点(例如肝窦内皮细胞和脾边缘区巨噬细胞),用于利用天然免疫耐受过程,以及几种携带抗原的纳米颗粒可以靶向这些细胞的策略。我们还讨论了携带免疫调节剂的纳米颗粒如何能够在其他抗原呈递细胞类型中激活耐受。最后,我们讨论了将动物研究数据转化为患者时必须考虑的一些重要方面。